X0609 4 2026-09-15 0001438533 Travere Therapeutics, Inc. TVTX 0001763494 Dube Eric M false C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO CA 92130 true true false false CHIEF EXECUTIVE OFFICER 1 Common Stock 2026-09-15 4 M 0 95666 23.34 A 528552 D Common Stock 2026-09-15 4 S 0 63498 61.9945 D 465054 D Common Stock 2026-09-15 4 S 0 28796 62.6553 D 436258 D Common Stock 2026-09-15 4 S 0 3102 63.6434 D 433156 D Common Stock 2026-09-15 4 S 0 270 65.31 D 432886 D Common Stock 2026-09-16 4 M 0 195841 23.34 A 628727 D Common Stock 2026-09-16 4 S 0 99716 63.2593 D 529011 D Common Stock 2026-09-16 4 S 0 96125 63.6389 D 432886 D Common Stock 2026-09-17 4 M 0 108493 23.34 A 541379 D Common Stock 2026-09-17 4 S 0 101691 64.5866 D 439688 D Common Stock 2026-09-17 4 S 0 6802 64.9508 D 432886 D Employee stock option (right to buy) 23.34 2026-09-15 4 M 0 95666 0 D 2029-01-04 Common Stock 95666 304334 D Employee stock option (right to buy) 23.34 2026-09-16 4 M 0 195841 0 D 2029-01-04 Common Stock 195841 108493 D Employee stock option (right to buy) 23.34 2026-09-17 4 M 0 108493 0 D 2029-01-04 Common Stock 108493 0 D This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The stock option is fully vested and exercisable. /s/ Elizabeth E. Reed, Attorney-in-Fact 2026-09-17